Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 2/20 | 0.48 |
| ▸ | GJB2 | P29033 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | CD209 | Q9NNX6 | 1/20 | 0.41 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.40 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.40 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.40 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.40 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 7/20 | 0.40 |
| ▸ | CDC25B | P30305 | 7/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 3/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.40 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25270558 | 1.00 | LGALS3 (0.48) | LGALS3GJB2SLC6A2CD209SSTR1 | |
| SCHEMBL19682250 | 0.91 | CD209 (0.45) | LGALS3GJB2SLC6A2CD209SSTR1 | |
| SCHEMBL29233702 | 0.90 | LGALS3 (0.48) | LGALS3GJB2SSTR1SSTR2SSTR4 | |
| SCHEMBL21258926 | 0.88 | CD209 (0.45) | LGALS3GJB2SLC6A2CD209SSTR1 | |
| SCHEMBL25964186 | 0.87 | LGALS3 (0.46) | LGALS3GJB2SSTR1SSTR2SSTR4 | |
| SCHEMBL22842843 | 0.87 | LGALS3 (0.46) | LGALS3GJB2SSTR1SSTR2SSTR4 | |
| SCHEMBL13557611 | 0.86 | LGALS3 (0.47) | LGALS3GJB2SLC6A2CD209SSTR1 | |
| SCHEMBL25964138 | 0.86 | LGALS3 (0.44) | LGALS3GJB2SSTR1SSTR2SSTR4 | |
| SCHEMBL21149838 | 0.85 | LGALS3 (0.47) | LGALS3GJB2SLC6A2CD209SSTR1 | |
| SCHEMBL13557604 | 0.85 | CD209 (0.47) | LGALS3GJB2SLC6A2CD209SSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192745-A1 | NOVEL INTERMEDIATES FOR THE PREPARATION OF GBS POLYSACCHARIDE ANTIGENS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-06-22 | — | — | US | disclosed |
| WO-2019012476-A1 | NOVEL INTERMEDIATES FOR THE PREPARATION OF GBS POLYSACCHARIDE ANTIGENS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2019-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192745-A1 | NOVEL INTERMEDIATES FOR THE PREPARATION OF GBS POLYSACCHARIDE ANTIGENS | CSGALNACT1, B3GAT3, ST3GAL3 | LGALS3 25/4885GJB2 3964/4885SLC6A2 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.